KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Common Equity (2016 - 2025)

Pfizer (PFE) has disclosed Common Equity for 17 consecutive years, with $92.8 billion as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity changed 0.26% to $92.8 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $92.8 billion, a 0.26% change, with the full-year FY2024 number at $88.5 billion, down 0.89% from a year prior.
  • Common Equity was $92.8 billion for Q3 2025 at Pfizer, up from $89.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $101.2 billion in Q2 2023 to a low of $68.9 billion in Q2 2021.
  • A 5-year average of $88.0 billion and a median of $89.3 billion in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: increased 24.4% in 2022, then decreased 11.4% in 2024.
  • Pfizer's Common Equity stood at $77.5 billion in 2021, then grew by 23.82% to $95.9 billion in 2022, then dropped by 6.91% to $89.3 billion in 2023, then fell by 0.89% to $88.5 billion in 2024, then increased by 4.86% to $92.8 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Common Equity are $92.8 billion (Q3 2025), $89.0 billion (Q2 2025), and $90.6 billion (Q1 2025).